Morning Call: Tradi...
Health Care: Drugs
Meridian Bioscience Inc. (VIVO: NASDAQ)
$21.85 -0.16 | -0.73%
05/20/13 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 21.85 |
| 52 Week High | 23.05 |
| 52 Week Low | 16.19 |
| Avg. Daily Vol. (Mil) | 0.17 |
| Beta (3 year) | 1.38 |
| Share Related Items | |
| Mkt Cap (Mil) | 906.06 |
| Shares Out (Mil) | 41.47 |
| Float (Mil) | 35.91 |
| Dividend Information | |
| Yield % | 3.50 |
| Annual Dividend | 0.76 |
| Payout Ratio | 89.00 |
| Financial Strength | |
| Quick Ratio | 3.50 |
| Current Ratio | 5.80 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | 0.00 |
| Valuation Ratios | |
| Price Earnings | 25.70 |
| Price/Sales | 5.08 |
| Price/Book | 6.11 |
| Price/Cash Flow | 21.10 |
| Per Share Data | |
| Earnings | 0.85 |
| Sales | 4.30 |
| Book Value | 3.58 |
| Cash Flow | 1.03 |
| Business Summary | |
|---|---|
| Meridian Bioscience, Inc. is a life science company engaged in the development, manufacture and distribution of diagnostic test kits; manufacture and distribution of bulk antigens, antibodies & reagents and manufacture of proteins & other biologicals. | |
| General Information | |
| 3471 River Hills Drive
Cincinnati, OH 45244 |
|
| www.meridianbioscience.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 510 | |
| CEO: John A. Kraeutler | |
| Short Interest | |
| Current Month (Mil) | 6.95 |
| Previous Month (Mil) | 6.51 |
| Short Interest Ratio (Days) | 36.00 |
| Management Effectiveness | |
| Return on Equity | 24.20 |
| Return on Assets | 21.60 |
| Return on Investments | 24.20 |
| Profitability | |
| Gross Margin | 68.30 |
| EBIT Margin | 30.00 |
| Profit Margin | 20.10 |
Portfolios with VIVO
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- ContributorHighest-Yielding Drug Stocks
- Userhulkkims Portfolio 1
- ContributorBarron's Insider Purchases ...
- UserSUPRATRADE 20 Dividend Stoc...
- UserSUPRATRADE HOT STOCKS (BUY ...
- ContributorDividend Stocks for the Wee...
- Userrussbow98 Portfolio 1
- ContributorBarron's Insider Purchases ...
- ContributorBarron's Insider Purchases ...
Latest VIVO Headlines from TheStreet
- Top Ranked Dividend Stock VIVO Enters Oversold Territory 04.26.13 | 11:04 am
- Meridian Bioscience Inc. Stock Upgraded (VIVO) 10.15.12 | 05:10 am
- Meridian Bioscience Inc. Stock Downgraded (VIVO) 08.22.12 | 05:08 am
- Meridian Bioscience Stock To Go Ex-dividend Tomorrow (VIVO) 05.01.12 | 09:05 am
- 8 Stocks Rising on Huge Volume 04.20.12 | 01:04 pm
- Meridian Bioscience Inc. Stock Upgraded (VIVO) 03.29.12 | 05:03 am
- Meridian Bioscience Rises On Unusually High Volume (VIVO) 02.01.12 | 03:02 pm
- Meridian Bioscience Stock To Go Ex-dividend Tomorrow (VIVO) 01.31.12 | 09:01 am
- Meridian Bioscience Stock To Go Ex-dividend Tomorrow (VIVO) 11.16.11 | 10:11 am
- Meridian Bioscience Stock Hits New 52-Week Low (VIVO) 10.03.11 | 09:10 am
Press Releases for VIVO
- Meridian Bioscience Recognized By Forbes As One Of America’s 100 Most Trustworthy Companies - Business Wire 03.28.13 | 11:03 am
- Meridian Bioscience Announces Illumigene® Group A Streptococcus And Illumigene® Group B Streptococcus Tests Categorized “Moderate Complexity” By FDA - Business Wire 03.18.13 | 11:03 am
- Bioline Launches ISOLATE II, A Precious Find For DNA And RNA Isolation - Business Wire 02.06.13 | 07:02 am
- Meridian Bioscience Reports First Quarter 2013 Operating Results And Reaffirms Fiscal 2013 Guidance - Business Wire 01.23.13 | 07:01 am
- Meridian Bioscience Successfully Completes Beta Trials For Two New Illumigene® Tests - Business Wire 12.13.12 | 02:12 pm
- Meridian Bioscience, Inc. Declares Regular Quarterly Dividend And Accelerates Payment Date To December 24, 2012 - Business Wire 12.04.12 | 10:12 am
- SensiFAST™ Genotyping Kit Exceed The Limit - Business Wire 11.28.12 | 07:11 am
- Meridian Bioscience Reports Fourth Quarter And Full-Year 2012 Operating Results, Declares Regular Cash Dividend, And Reaffirms Fiscal 2013 Guidance - Business Wire 11.08.12 | 07:11 am
- Meridian Bioscience Receives FDA Clearance For New Molecular Test: Illumigene® Group A Strep - Business Wire 09.17.12 | 03:09 pm
- Meridian Bioscience Provides Sales And Earnings Guidance For Fiscal 2013 And Reaffirms Fiscal 2012 Guidance - Business Wire 08.28.12 | 07:08 am
Partner Headlines for VIVO
- Meridian Bioscience Earnings: Here’s Why Investors Don’t Like These Results - Wall St. Cheat Sheet 04.25.13 | 02:04 am
- FDA Clears Meridian Ilumigene GAS - Analyst Blog - NASDAQ 09.20.12 | 04:09 pm
- Gilead REITERATED a Top Pick and 4 Stock Analyses Trending Now - Wall St. Cheat Sheet 07.27.12 | 12:07 pm
- Starbucks DOWNGRADED to Neutral and 4 Downgraded Shares Attracting Attention - Wall St. Cheat Sheet 07.27.12 | 03:07 am
- Meridian Bioscience Receives FDA Clearance for New Legionella Test - Benzinga 02.27.12 | 01:02 pm
- UPDATE: Wedbush Downgrades Meridian Bioscience to Underperform - Benzinga 01.31.12 | 09:01 am
- Dividend Stocks That Combine Growth And Income - Seeking Alpha 01.20.12 | 08:01 am
- FDA OKs Meridian's GDH Test - Analyst Blog - Zacks 01.05.12 | 10:01 am
- 30 'Overdue' Dividend Increases -- Will History Repeat Itself? - Seeking Alpha 08.19.11 | 06:08 pm
- FDA OKs Meridian C. difficile Test - Analyst Blog - Zacks 05.13.11 | 09:05 am
